Login / Signup

A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.

Ronan P McLaughlinJichao HeVera E van der NoordJevin RedelJohn A FoekensJohn W M MartensMarcel SmidYinghui ZhangBob van de Water
Published in: Breast cancer research : BCR (2019)
Our results highlight that dual inhibition of cdc7 and CDK9 by PHA-767491 is a potential strategy for targeting TNBC resistant to EGFR-TKIs.
Keyphrases
  • cell cycle
  • small cell lung cancer
  • epidermal growth factor receptor
  • tyrosine kinase
  • cell proliferation
  • high throughput
  • genome wide
  • cancer therapy